Clinical Trials

982 enrolled 15 charts

Prostatic Neoplasms

NCT02531516 2026-03-19

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled

Prostatic Neoplasms

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Carcinoma, Renal Cell

NCT04658862 2026-03-19

SunRISe-2

518 enrolled

Urinary Bladder Neoplasms

NCT05714202 2026-03-19

SunRISe-3

1,135 enrolled

Urinary Bladder Neoplasms

NCT06629779 2026-03-19

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT07218380 2026-03-19

FORAGER-2

450 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06510374 2026-03-18

ABLE-32

454 enrolled

Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06970847 2026-03-18

AMPLIFY

220 enrolled

Prostatic Neoplasms

NCT07480356 2026-03-18

ADVANCED-3

284 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT05794906 2026-03-17

ARASTEP

985 enrolled

Biochemically Recurrent Prostate Cancer

NCT06211764 2026-03-17

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07342517 2026-03-17

RESCUE

Phase 3 Withdrawn

Neoplasms, Urologic Neoplasms

NCT03748641 2026-03-16

MAGNITUDE

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04452591 2026-03-16

BOND-003

190 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06056830 2026-03-16

CLARIFY

383 enrolled

Prostatic Neoplasms

NCT07227402 2026-03-16

LITESPARK-033

904 enrolled

Carcinoma, Carcinoma, Renal Cell

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT04557059 2026-03-13

PRIMORDIUM

693 enrolled

Prostatic Neoplasms

NCT06319820 2026-03-13

MoonRISe-1

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06925737 2026-03-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07011719 2026-03-13

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

720 enrolled

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

NCT07225946 2026-03-13

KLK2-PASenger

800 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT05884398 2026-03-12

LIBERTAS

420 enrolled

Metastatic Castrate-sensitive Prostate Cancer

NCT04720157 2026-03-11

PSMAddition

1,145 enrolled

Prostatic Neoplasms

NCT04821622 2026-03-11

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT06136624 2026-03-11

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT07464145 2026-03-11

RESCUE

393 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT03142334 2026-03-10

KEYNOTE-564

994 enrolled 10 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07000149 2026-03-10

eVOLVE-RCC02

1,116 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT06136650 2026-03-09

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT07028853 2026-03-04

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT07393542 2026-03-03

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

462 enrolled

Carcinoma, Transitional Cell

NCT04736199 2026-02-27

ARANOTE

669 enrolled 16 charts

Prostatic Neoplasms

NCT07213674 2026-02-27

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

750 enrolled

Prostatic Neoplasms

NCT05939414 2026-02-24

PSMA-DC

450 enrolled

Oligometastatic Prostate Cancer (OMPC)

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT06960577 2026-02-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Urinary Bladder Neoplasms

NCT04689828 2026-02-20

PSMAfore

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT04876651 2026-02-20

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Phase 3 Terminated

16 enrolled

Prostatic Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07419295 2026-02-19

TroFuse-031

590 enrolled

Urinary Bladder Neoplasms

NCT06235099 2026-02-18

Solar-Recur

235 enrolled